Senior Vice President, Business Development and Licensing
Dr. Bryan became our Senior Vice President of Business Development in March 2017. Prior to joining Sucampo, he served as SVP BD of Lupin Inc., where he had responsibility for business development for the brand division, since 2015.
From 2005 to 2015, Dr. Bryan was Vice President Business Development of Supernus Pharmaceuticals Inc., a development and commercial stage CNS specialty company. He also held leadership roles of increasing responsibility from 2000 to 2005 at Shire Laboratories, the drug delivery division of Shire Pharmaceuticals.
Prior to Shire Dr. Bryan worked at AAI from 1993 to 2000 in various roles in product development and business development. Prior to AAI he began his career in formulation development at Schering Plough in 1990.
Dr. Bryan serves on the Board of Directors of Afecta Pharmaceuticals and Clemson University’s Advisory Board to the Spiro Institute for Entrepreneurial Innovation and Leadership.
Dr. Bryan earned his BS degree in Zoology from Clemson University and a Ph.D. from the Medical University of South Carolina.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.